WESTON (dpa-AFX) - Drugmaker Biogen Idec (BIIB) Thursday announced top-line results from the Phase 2 acute optic neuritis or AON RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.
Anti-LINGO-1 demonstrated an improvement in the study's primary endpoint, recovery of optic nerve latency, relative to placebo. The study showed no effect on secondary endpoints, including change in thickness of the retinal layers and visual function.
AON damages the optic nerve, causing loss of the myelin sheath and axonal injury, and may result in loss of visual function. It is considered a good clinical model to measure the hypothesized mechanisms of action of anti-LINGO-1, remyelination and neuroprotection.
RENEW was designed to study anti-LINGO-1's ability to enable repair of an optic nerve lesion by way of axonal remyelination following the onset of a first episode of AON. RENEW is part of the anti-LINGO-1 Phase 2 clinical development program, which includes the SYNERGY trial in multiple sclerosis.
Anti-LINGO-1 was generally well tolerated. The overall incidence and severity of adverse events was comparable across treatment arms.
Copyright RTT News/dpa-AFX
© 2015 AFX News
